

ALASKA STATE LEGISLATURE

Session

State Capitol, Rm. 418
Juneau, AK 99801
(907) 465-3892
Fax: (907) 465-6595

Interim

1500 W. Benson Blvd.
Anchorage, AK 99503
(907) 269-0234
Fax: (907) 269-0238



House Finance Committee

Dept. of Law
Finance Subcommittee
Chairman

Dept. of Administration
Finance Subcommittee
Chairman

Rep.Jason.Grenn@akleg.gov

REPRESENTATIVE JASON GRENN

SECTIONAL ANALYSIS

House Bill 43 ver J

The Right to Try: New Drugs for the Terminally Ill

Section 1: Prohibits disciplinary action of physicians by the State Medical Board for prescribing, dispensing or administering an investigational drug, biological product or device to terminally ill patients that are ineligible or unable to participate in a current clinical trial, have considered all other treatment options approved by the FDA and have provided written consent.

Defines “investigational drugs, biological products and devices” as those that have successfully completed Phase 1 of the FDA drug review process and remain in ongoing Phase 2 or 3 clinical trials or the marketing application process, but have not been approved for general use.

Defines “terminal illness” as a disease that will result in death in the near future or permanent state of unconsciousness from which recovery is unlikely.

Section 2: Establishes immunity for physicians, medical team members, manufacturers and distributors in the case of injury or death of a terminally ill patient from the use of an investigational drug, biological product or device, provided informed consent was obtained from the patient and notice of immunity was given in advance.

Establishes immunity for physicians and manufacturers who choose not to participate in the distribution of an investigational drug, biological product or device.

Section 3: Amends statute limiting the sale and distribution of new drugs (AS 17.20.110) so as not to apply to physicians prescribing or administering investigational drugs under the conditions established in Section 1.

Section 4: Prohibits the Department of Health and Social Services from requiring a licensed health care facility to increase its services solely to accommodate physicians prescribing, dispensing or administering investigational drugs to a patient.